The first wave of the GLP-1 era in the US was defined by a shortage. Patients often waited for backlogs of prescriptions, pharmacies rationed supply, and demand outstripped what manufacturers could supply. That period is mostly over. Tirzepatid and semaglutide are now regularly available, the range of clinical options has expanded, and platforms such as Mochi Health (…)
The next phase of the GLP-1 Boom is about choice, access and monitoring
